WELCOME TO Million Health Pharmaceuticals

Mechanism of action

Bevarest comprises an active compound like Bevacizumab which binds to VEGF and avoid the communication of VEGF to its receptors like Flt-1 & KDR) present on the surface of the cells This interaction prevents endothelial cell multiplication and new blood vessel production occurs Hence in counts cessation of metastatic cancer cells development happens


The volume of distribution is 2.9 (22%) L


The Bevacizumab half life period is 20days (11 to 50days)

Brand : Bevarest
Ingredients : Bevacizumab
Strength : 400mg/16ml & 100mg/4ml
Manufactured : Emcure Pharmaceuticals
Package : 400mg of Bevacizumab containing vial

Key point

Avoid administration of Bevarest before at least 28 days following surgery and the wound is completely cured

Metastatic colorectal carcinoma

Concomitant use with 5-fluorouracil based chemotherapy is the usual dosage of Bevarest : While concomitant use with bolus IFL the dose is 5mg/kg of Bevarest for every 2 weeks IV. While in combination with FOLFOX4 the dose is 10mg/kg of Bevarest for every 2 weeks IV 5mg/kg IV Bevarest for every 2 weeks or 7.5 mg/kg Bevarest as IV every 3 weeks by concurrently used with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy

Non-small cell lung cancer

While combining with carboplatin and paclitaxel : The Bevarest usual dosage is 15mg/kg IV for every 3 weeks by


For every 2 weeks : 10mg/kg of Bevarest administered IV

Metastatic cervical cancer

Combining with paclitaxel and cisplatin or with paclitaxel and topotecan : The drug Bevarest usual dosage is 15mg/kg of Bevarest given intravenously for every 3 weeks

Metastatic renal cell cancer

Concurrent use with interferon alfa : The Bevarest usual dosage is 10mg/kg IV for every 2 weeks

Epithelial ovarian, fallopian tube or peritoneal cancer

Platinum opposing: Concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan :The Bevarest regular dosage is 10mg/kg of Bevarest for every 2 weeks Or Combining with topotecan : The Bevarest regular dosage 15mg/kg of Bevarest given through IV for every 3 weeks Platinum responsive concomitant with carboplatin and paclitaxel for 6 to 8 cycles : The drug Bevarest recommended dosage of is 15mg/kg given IV for 3 weeks Combining with gemcitabine & carboplatin for 6 to 10 cycles : The Bevarest recommended dosage is 15mg/kg of Bevarest given IV for 3 weeks

Preparation & administration

Bevarest is intravenous solution At initial infusion: given IV infusion over 90 minutes Following infusions: give second infusion over 60 minutes, if tolerated Administer all following infusion over 30minutes Bevarest IV infusion is prepared in aseptic condition Bevarest 400mg containing 16ml solution whereas 100mg containing 4ml Bevarest dilute into 100ml of 0.9% NS Do not dilute with dextrose solution Dispose the remaining portion of medicine which is left in a vial

Side effects

Gastrointestinal perforation and fistulae Surgery and wound healing complication Hemorrhage Arterial thromboembolic events Venous thromboembolic events Hypertension Posterior reversible encephalopathy syndrome Renal injury & Proteinuria Infusion reactions Ovarian failure Congestive heart failure Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysaesthesia



There are some complications occurred during treatment with Bevarest , care should be taken Arterial thromboembolic events: cessation of treatment with Bevarest in patients who are suffered with severe ATE. Venous thromboembolic events: Toxicity Incidence should be detected; If severe condition therapy should be stopped. Hemorrhage: While on Bevarest treatment some Serious hemorrhages will occur like GI hemorrhage, hemoptysis, Hematemesis, CNS hemorrhage, nose bleeding & vaginal bleeding. Hence Discontinue the treatment.

Hypertension: Bp is increased in patients who are receiving Bevarest therapy, must be frequently check up with blood pressure and provided with alternative medication for correct the pressure. In hypertension crisis or encephalopathy should be discontinue the treatment.

Posterior reversible encephalopathy syndrome Embryo fetal toxicity occurs : During pregnancy condition Bevarest is contraindicated which produce fetal harm. Ovarian failure: The patients who are receiving Bevarest may have a chance of getting ovarian failure. Congestive heart failure: the drug combination with anthracycline based chemotherapy, treatment with Bevarest must not be used. Bevarest treatment should be stopped while CHF occurs.

Quick Contact

Prescription upload

Top Products


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.